Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Meet the Justice Gang: “Superman” stars introduce their dynamic super-trio (exclusive) Fans Rally Around Valerie Bertinelli ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Recipients of the Pfizer mRNA vaccine experienced more all-cause deaths within the first 100 days post-vaccination than ...